Expertise in
2
conditions

Zhongsheng H. Tong

Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
Expertise in
2
conditions
Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 

Overview

Zhongsheng Tong practices practicing medicine in Beijing, China.

Tong is highly rated in 2 conditions, according to our data. Their clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Pneumonia, Agranulocytosis, and Lung Transplant.

They are actively involved in clinical research, co-authoring 164 peer reviewed articles and participating in 3 clinical trials.

Locations

Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100730, China
Other Locations
No. 305 East Zhongshan Road, Nanjing, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
A Phase 3, Randomized, Double-Blind Study of Trilaciclib or Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (PRESERVE 2)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 3
A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors
A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 Combine With Pembrolizumab Injection in Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Unknown
Publish Date: April 15, 2024
Intervention Type: Biological
Study Drugs: TJ107, Pembrolizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

164 Total Publications

Retraction notice to "Circ_0084653 promotes the tumor progression and immune escape in triple-negative breast cancer via the deubiquitination of MYC and upregulation of SOX5" [International Journal of Biological Macromolecules 280 (2024) 135655].
Retraction notice to "Circ_0084653 promotes the tumor progression and immune escape in triple-negative breast cancer via the deubiquitination of MYC and upregulation of SOX5" [International Journal of Biological Macromolecules 280 (2024) 135655].
Journal: International journal of biological macromolecules
Published: July 21, 2026

Frequently Asked Questions about Zhongsheng H. Tong

Is Zhongsheng H. Tong a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Zhongsheng H. Tong is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Zhongsheng H. Tong participate in research or clinical trials?

Yes. Zhongsheng H. Tong has published 164 articles and abstracts on conditions like Breast Cancer. You can view a list of Zhongsheng H. Tong's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tong's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile